The retina is one of the tissues ATH434 has been investigated with its iron chelators, but nothing has been published, only mentioned in the annular report. Here is a paper from China telling what has been published by other scientists. As you may remember, Prof. Finkelstein has made a couple of papers from eyes but nothing about ATH434 or other molecules of ATH. The free copy can be seen as a pdf.

Review

Int J Ophthalmol

. 2023 Nov 18;16(11):1899-1910.

doi: 10.18240/ijo.2023.11.24. eCollection 2023.

Therapeutic potential of iron chelators in retinal vascular diseases

Yan Li ^{1 2}, Zi-Xuan Cheng ¹, Ting Luo ^{1 2}, Hong-Bin Lyu ¹

Affiliations expand

• PMID: 38028518

PMCID: PMC10626364 DOI: 10.18240/ijo.2023.11.24

Abstract

Iron is one of the necessary metal elements in the human body. There are numerous factors that control the balance of iron metabolism, and its storage and transportation mechanisms are intricate. As one of the most energy-intensive tissues in the body, the retina is susceptible to iron imbalance. The occurrence of iron overload in the retina leads to the generation of a significant quantity of reactive oxygen species. This will aggravate local oxidative stress and inflammatory reactions and even lead to ferroptosis, eventually resulting in retinal dysfunction. The blood-retina-retinal barrier is eventually harmed by oxidative stress and elevated inflammation, which are characteristics of retinal vascular disorders. The pathophysiology of retinal vascular disorders may be significantly influenced by iron. Recently, iron-chelating agents have been found to have antioxidative and anti-inflammatory actions in addition to iron chelating. Therefore, iron neutralization is considered to be a new and potentially useful therapeutic strategy. This article reviews the iron overload in retinal vascular diseases and discusses the therapeutic potential of iron-chelating agents.